Education
About Us
Working with TipRanks
Follow Us
Kazia Therapeutics Limited (KZIA)
NASDAQ:KZIA
Top Page
Kazia Therapeutics
(NASDAQ:KZIA)
Rating:31Underperform
Price Target:―
Positive Factors
Market Opportunities
Paxalisib is being evaluated for treating resistant triple negative breast cancer, which presents a significant market opportunity, and data from this study could be impactful.
Research and Development
A research grant was awarded to Kazia to evaluate paxalisib as a treatment for Parkinson's disease, highlighting a novel opportunity for the company.
Negative Factors
Capital Requirements
Additional capital will likely be required to continue clinical operations, which can occur in various forms.
Financial Challenges
The financing market remains difficult due to current market conditions and Kazia’s market cap.
Kazia Therapeutics (KZIA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.18M
Dividend YieldN/A
Average Volume (3M)35.51K
Price to Earnings (P/E)―
Beta (1Y)1.33
Revenue GrowthN/A
EPS Growth19.58%
CountryUS
Employees9
SectorHealthcare
Sector Strength40
IndustryBiotechnology
Share Statistics
EPS (TTM)-33.32
Shares Outstanding1,117,859
10 Day Avg. Volume12,283
30 Day Avg. Volume35,513
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.04
Price to Sales (P/S)0.00
P/FCF Ratio-0.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$15.00Price Target Upside301.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Kazia Therapeutics Business Overview & Revenue Model
Company DescriptionKazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
How the Company Makes MoneyKazia Therapeutics primarily generates revenue through the development and potential commercialization of its drug candidates. The company seeks to advance its therapies through clinical trials and, upon successful results and regulatory approval, aims to license its drugs to larger pharmaceutical companies or bring them to market directly. Key revenue streams include milestone payments, royalties from licensing agreements, and potential sales revenue of approved drugs. Partnerships with research institutions and pharmaceutical companies also play a crucial role in funding and advancing their drug development programs.
Kazia Therapeutics Financial Statement Overview
Summary
Kazia Therapeutics is facing financial challenges with declining revenues, persistent losses, and negative equity. The company struggles with cash flow generation and financial stability, which could affect its ability to sustain operations without significant changes or external funding.Income Statement
Kazia Therapeutics has shown declining revenue over the years with a significant drop in total revenue in the most recent period. The company is experiencing a negative net profit margin, indicating it is not profitable. Moreover, both EBIT and EBITDA margins are negative, highlighting operational inefficiencies and challenges in controlling costs.20
Very Negative
Balance Sheet
The company's financial structure is concerning, with negative stockholders' equity in the latest period, indicating liabilities exceed assets. The debt-to-equity ratio is not applicable due to negative equity, which poses a financial risk. Moreover, the equity ratio is negative, underscoring the financial instability and leverage issues.30
Negative
Cash Flow
There is a negative operating cash flow and free cash flow, indicating that the company is not generating sufficient cash from its operations. The free cash flow growth rate is negative, suggesting worsening liquidity and inability to cover expenses without external financing.25
Negative
| Breakdown | ||||
| Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 2.31M | 555.00 | 25.00 | 15.18M | 1.06K | Gross Profit |
| 2.31M | 555.00 | 25.00 | 15.18M | 1.06K | EBIT |
| 0.00 | -24.12M | -26.70M | -6.38M | -12.53M | EBITDA |
| -26.77M | -22.28M | -23.51M | -5.11M | -11.11M | Net Income Common Stockholders |
| -26.78M | -20.47M | -24.65M | -8.42M | -12.47M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 1.66M | 5.24M | 7.36M | 27.59M | 8.76M | Total Assets |
| 21.59M | 28.09M | 34.96M | 58.09M | 23.06M | Total Debt |
| 634.00K | 1.80M | 1.84M | 0.00 | 0.00 | Net Debt |
| -1.02M | -3.44M | -5.52M | -27.59M | -8.76M | Total Liabilities |
| 31.60M | 16.03M | 16.32M | 20.24M | 8.94M | Stockholders Equity |
| -10.02M | 12.05M | 18.64M | 37.85M | 14.13M |
| Cash Flow | Free Cash Flow | |||
| -9.58M | -15.16M | -22.76M | -9.11M | -8.81M | Operating Cash Flow |
| -9.58M | -15.16M | -22.76M | -9.11M | -8.81M | Investing Cash Flow |
| 0.00 | 0.00 | -2.36M | 0.00 | 0.00 | Financing Cash Flow |
| 5.99M | 12.97M | 3.73M | 28.11M | 12.14M |
Kazia Therapeutics Technical Analysis
Neutral
3.74
Price Trends
3.83
Negative
5.03
Negative
13.31
Negative
Market Momentum
-0.05
Negative
52.98
Neutral
61.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KZIA, the sentiment is Neutral. The current price of 3.74 is above the 20-day moving average (MA) of 3.54, below the 50-day MA of 3.83, and below the 200-day MA of 13.31, indicating a neutral trend. The MACD of -0.05 indicates Negative momentum. The RSI at 52.98 is Neutral, neither overbought nor oversold. The STOCH value of 61.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for KZIA.
Kazia Therapeutics Risk Analysis
Kazia Therapeutics disclosed 37 risk factors in its most recent earnings report. Kazia Therapeutics reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
Holders of the ADSs are not treated as holders of our ordinary shares. Q2, 2024
2.
We have a history of operating losses and we expect to continue to incur losses and may never be profitable. Q2, 2024
3.
If the Company fails to comply with the rules under the Sarbanes-Oxley Act of 2002 related to accounting controls and procedures in the future, or, if the Company discovers material weaknesses and other deficiencies in our internal control and accounting procedures, the price of the ADSs could decline significantly and raising capital could be more difficult. Q2, 2024
Kazia Therapeutics Peers Comparison
Overall Rating
UnderperformOutperform
Sector (53)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $5.14B | 3.23 | -45.01% | 2.85% | 17.55% | -0.69% | |
48 Neutral | $3.77M | ― | -714.96% | ― | 978.39% | 69.65% | |
45 Neutral | $768.88K | ― | -89.21% | ― | -83.72% | 99.56% | |
43 Neutral | $4.63M | ― | -53.16% | ― | -1.56% | 5.01% | |
31 Underperform | $4.18M | ― | -2639.52% | ― | ― | 19.58% | |
| $7.48M | ― | ― | ― | ― | |||
| $6.77M | ― | -82.81% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
KZIA
Kazia Therapeutics
3.74
-8.36
-69.09%
BDRX
Biodexa Pharmaceuticals
1.15
-23.35
-95.31%
SONN
Sonnet BioTherapeutics Holdings
1.19
-12.01
-90.98%
XBIO
Xenetic Biosciences
2.88
-0.89
-23.61%
NLSP
NLS Pharmaceutics
2.08
-4.86
-70.03%
KTTA
Pasithea Therapeutics Corp
0.91
-4.94
-84.44%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.